The price-to-earnings ratio for Neurocrine Biosciences, Inc (NASDAQ: NBIX) is 35.28x, which is above its average ratio. Moreover, the 36-month beta value for NBIX is 0.31. Analysts have varying opinions on the stock, with 15 analysts rating it as a “buy,” 6 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for NBIX is 96.79M and currently, short sellers hold a 2.48% of that float. On February 21, 2025, NBIX’s average trading volume was 1.16M shares.
NBIX) stock’s latest price update
Neurocrine Biosciences, Inc (NASDAQ: NBIX)’s stock price has soared by 1.62 in relation to previous closing price of 114.26. Nevertheless, the company has seen a loss of -0.91% in its stock price over the last five trading days. fool.com reported 2025-02-10 that Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn’t been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech’s shares, leaving them with a more than 3% loss in price on the day.
NBIX’s Market Performance
NBIX’s stock has fallen by -0.91% in the past week, with a monthly drop of -20.41% and a quarterly drop of -1.13%. The volatility ratio for the week is 2.56% while the volatility levels for the last 30 days are 3.05% for Neurocrine Biosciences, Inc. The simple moving average for the past 20 days is -14.21% for NBIX’s stock, with a -12.64% simple moving average for the past 200 days.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Deutsche Bank repeating the rating for NBIX by listing it as a “Hold.” The predicted price for NBIX in the upcoming period, according to Deutsche Bank is $138 based on the research report published on February 11, 2025 of the current year 2025.
Raymond James, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $155. The rating they have provided for NBIX stocks is “Outperform” according to the report published on October 10th, 2024.
Piper Sandler gave a rating of “Overweight” to NBIX, setting the target price at $159 in the report published on August 29th of the previous year.
NBIX Trading at -14.74% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.50% of loss for the given period.
Volatility was left at 3.05%, however, over the last 30 days, the volatility rate increased by 2.56%, as shares sank -20.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.16% lower at present.
During the last 5 trading sessions, NBIX fell by -0.91%, which changed the moving average for the period of 200-days by -16.96% in comparison to the 20-day moving average, which settled at $135.35. In addition, Neurocrine Biosciences, Inc saw -14.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from Cooke Julie, who sale 1,551 shares at the price of $116.78 back on Feb 13 ’25. After this action, Cooke Julie now owns 19,544 shares of Neurocrine Biosciences, Inc, valued at $181,129 using the latest closing price.
GORMAN KEVIN CHARLES, the Director of Neurocrine Biosciences, Inc, sale 5,844 shares at $116.69 during a trade that took place back on Feb 13 ’25, which means that GORMAN KEVIN CHARLES is holding 521,618 shares at $681,914 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc stands at 0.14. The total capital return value is set at 0.18. Equity return is now at value 14.16, with 9.51 for asset returns.
Based on Neurocrine Biosciences, Inc (NBIX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at 1.31. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 526.36.
Currently, EBITDA for the company is 610.1 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 5.01. The receivables turnover for the company is 4.92for trailing twelve months and the total asset turnover is 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.40.
Conclusion
To wrap up, the performance of Neurocrine Biosciences, Inc (NBIX) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
